by Mat Dirjish
Sleep-medicine technology company HoneyNaps claims its SOMNUM AI-based sleep disorder diagnostic support software significantly reduces clinical trial timelines and costs via enhanced data-analysis efficiency. Recently gaining clearance from the US Food and Drug Administration (FDA), the application automatically analyzes polysomnography (PSG) data, enabling a system to identify sleep stages and events such as apnea, hypopnea, and arousals.
HoneyNaps Accelerates Clinical Trial Pipelines with FDA-Cleared AI “SOMNUM”
Traditionally, PSG scoring requires specialists to manually review and classify data for more than three to four hours per case, resulting in high labor and time costs. SOMNUM automates this process, shortening scoring time to minutes. According to the company, pharmaceutical companies and medical device manufacturers using SOMNUM are able to accelerate clinical trial pipelines, increase data-processing speed by more than 70%, and reduce overall study timelines by approximately 50%. Also, labor costs and quality-control (QC) expenses also drop by 80% to 90%.
HoneyNaps is also offering an AI-based re-scoring (verification scoring) service for already-scored PSG datasets. This business model provides an objective check on the accuracy of existing scoring results. For further information, contact HoneyNaps USA via email. Also, visit the HoneyNaps website.
Mat Dirjish Online 